Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
David M. Goldenberg & Robert M. Sharkey. (2019) Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan. mAbs 11:6, pages 987-995.
Read now
Read now
Surinder K. Sharma & Kenneth D. Bagshawe. (2017) Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination. Expert Opinion on Biological Therapy 17:1, pages 1-13.
Read now
Read now
Articles from other publishers (26)
Ritwik Maiti, Bhumika Patel, Nrupesh Patel, Mehul Patel, Alkesh Patel & Nirav Dhanesha. (2023) Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities. Archives of Pharmacal Research 46:5, pages 361-388.
Crossref
Crossref
Louis Jolivet, Imène Ait Mohamed Amar, Catherine Horiot, Fanny Boursin, Cyril Colas, Stéphanie Letast, Caroline Denevault-Sabourin, Emilie Allard-Vannier, Nicolas Joubert & Nicolas Aubrey. (2022) Intra-Domain Cysteines (IDC), a New Strategy for the Development of Original Antibody Fragment–Drug Conjugates (FDCs). Pharmaceutics 14:8, pages 1524.
Crossref
Crossref
M. Murali, A. R. Kumar, B. Nair, K. Pavithran, A. R. Devan, G. K. Pradeep & L. R. Nath. (2021) Antibody–drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance. Clinical and Translational Oncology 24:3, pages 407-431.
Crossref
Crossref
Letizia Polito, Giulia Calafato, Massimo Bortolotti, Cecilia Chiarelli Olivari, Stefania Maiello & Andrea Bolognesi. (2021) Antibody Conjugates for Sarcoma Therapy: How Far along Are We?. Biomedicines 9:8, pages 978.
Crossref
Crossref
Brandon M. Bordeau, Yujie Yang & Joseph P. Balthasar. (2021) Transient Competitive Inhibition Bypasses the Binding Site Barrier to Improve Tumor Penetration of Trastuzumab and Enhance T-DM1 Efficacy. Cancer Research 81:15, pages 4145-4154.
Crossref
Crossref
Edit Tarcsa, Magali R. Guffroy, Hadi Falahatpisheh, Colin Phipps & John C. Kalvass. (2020) Antibody-drug conjugates as targeted therapies: Are we there yet? A critical review of the current clinical landscape. Drug Discovery Today: Technologies 37, pages 13-22.
Crossref
Crossref
Thomas M. Cardillo, Diane L. Rossi, Maria B. Zalath, Donglin Liu, Roberto Arrojo, Robert M. Sharkey, Chien-Hsing Chang & David M. Goldenberg. (2020) Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer. Oncotarget 11:43, pages 3849-3862.
Crossref
Crossref
Sahar Roozbehi, Simin Dadashzadeh, Manouchehr Mirshahi, Majid Sadeghizadeh & Reza H. Sajedi. (2020) Targeted anticancer prodrug therapy using dextran mediated enzyme–antibody conjugate and β-cyclodextrin-curcumin inclusion complex. International Journal of Biological Macromolecules 160, pages 1029-1041.
Crossref
Crossref
Nicolas Joubert, Alain Beck, Charles Dumontet & Caroline Denevault-Sabourin. (2020) Antibody–Drug Conjugates: The Last Decade. Pharmaceuticals 13:9, pages 245.
Crossref
Crossref
Jie Zhou, Jing Hou, Yunlong Liu & Jun Rao. (2020) Targeted delivery of β-glucosidase-loaded magnetic nanoparticles: effect of external magnetic field duration and intensity. Nanomedicine 15:21, pages 2029-2040.
Crossref
Crossref
Sara S Bashraheel, Alexander Domling & Sayed K Goda. (2020) Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine. Biomedicine & Pharmacotherapy 125, pages 110009.
Crossref
Crossref
Alain Beck, Charles Dumontet & Nicolas Joubert. (2020) Les immunoconjugués en oncologie. médecine/sciences 35:12, pages 1043-1053.
Crossref
Crossref
Efrat T. Harel, Penelope M. Drake, Robyn M. Barfield, Irene Lui, Shauna Farr-Jones, Laura Van’t Veer, Zev J. Gartner, Evan M. Green, André Luiz Lourenço, Yifan Cheng, Byron C. Hann, David Rabuka & Charles S. Craik. (2019) Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer. Antibodies 8:4, pages 54.
Crossref
Crossref
Yilan Ma, Mingjiong Zhang, Jiayan Wang, Xiaochen Huang, Xingwang Kuai, Xiaojuan Zhu, Yuan Chen, Lizhou Jia, Zhenqing Feng, Qi Tang & Zheng Liu. (2019) High-Affinity Human Anti-c-Met IgG Conjugated to Oxaliplatin as Targeted Chemotherapy for Hepatocellular Carcinoma. Frontiers in Oncology 9.
Crossref
Crossref
Serengulam V. Govindan, Thomas M. Cardillo & David M. Goldenberg. 2019. Cytotoxic Payloads for Antibody – Drug Conjugates. Cytotoxic Payloads for Antibody – Drug Conjugates
166
186
.
Aman P. Singh & Dhaval K. Shah. (2019) A “Dual” Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC. Journal of Pharmaceutical Sciences 108:7, pages 2465-2475.
Crossref
Crossref
Wenjuan Dong, Jianyou Shi, Ting Yuan, Baowen Qi, Jiying Yu, Jingying Dai & Lin He. (2019) Antibody-drug conjugates of 7-ethyl-10-hydroxycamptothecin: Sacituzumab govitecan and labetuzumab govitecan. European Journal of Medicinal Chemistry 167, pages 583-593.
Crossref
Crossref
Andrew T. Lucas, Ryan Robinson, Allison N. Schorzman, Joseph A. Piscitelli, Juan F. Razo & William C. Zamboni. (2019) Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients. Antibodies 8:1, pages 3.
Crossref
Crossref
Nicolas Aubrey, Emilie Allard-Vannier, Camille Martin, Francesca Bryden, Stéphanie Letast, Cyril Colas, Zineb Lakhrif, Nils Collinet, Isabelle Dimier-Poisson, Igor Chourpa, Marie-Claude Viaud-Massuard & Nicolas Joubert. (2018)
Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer
in Vitro
. Bioconjugate Chemistry 29:11, pages 3516-3521.
Crossref
Crossref
Ying Fu & Mitchell Ho. (2018) DNA damaging agent-based antibody-drug conjugates for cancer therapy. Antibody Therapeutics 1:2, pages 43-53.
Crossref
Crossref
Robert M. Sharkey, Serengulam V. Govindan, Thomas M. Cardillo, Jennifer Donnell, Jing Xia, Edmund A. Rossi, Chien-Hsing Chang & David M. Goldenberg. (2018) Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody–Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130). Molecular Cancer Therapeutics 17:1, pages 196-203.
Crossref
Crossref
Thomas M. Cardillo, Serengulam V. Govindan, Maria B. Zalath, Diane L. Rossi, Yang Wang, Chien-Hsing Chang & David M. Goldenberg. (2018) IMMU-140, a Novel SN-38 Antibody–Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma. Molecular Cancer Therapeutics 17:1, pages 150-160.
Crossref
Crossref
Penelope M. Drake & David Rabuka. (2017) Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends. BioDrugs 31:6, pages 521-531.
Crossref
Crossref
Allyson J. Ocean, Alexander N. Starodub, Aditya Bardia, Linda T. Vahdat, Steven J. Isakoff, Michael Guarino, Wells A. Messersmith, Vincent J. Picozzi, Ingrid A. Mayer, William A. Wegener, Pius Maliakal, Serengulam V. Govindan, Robert M. Sharkey & David M. Goldenberg. (2017) Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer 123:19, pages 3843-3854.
Crossref
Crossref
Aditya BardiaIngrid A. MayerJennifer R. DiamondRebecca L. MorooseSteven J. IsakoffAlexander N. StarodubNikita C. ShahJoyce O’ShaughnessyKevin KalinskyMichael GuarinoVandana AbramsonDejan JuricSara M. TolaneyJordan BerlinWells A. MessersmithAllyson J. OceanWilliam A. WegenerPius MaliakalRobert M. SharkeySerengulam V. GovindanDavid M. GoldenbergLinda T. Vahdat. (2017) Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology 35:19, pages 2141-2148.
Crossref
Crossref
Aditya BardiaIngrid A. MayerJennifer R. DiamondRebecca L. MorooseSteven J. IsakoffAlexander N. StarodubNikita C. ShahJoyce O’ShaughnessyKevin KalinskyMichael GuarinoVandana AbramsonDejan JuricSara M. TolaneyJordan BerlinWells A. MessersmithAllyson J. OceanWilliam A. WegenerPius MaliakalRobert M. SharkeySerengulam V. GovindanDavid M. GoldenbergLinda T. Vahdat. (2017) Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology 2017:2, pages 2141-2148.
Crossref
Crossref